The therapeutic window problem with RAS inhibition has stymied oncology for decades, and Adlai Nortye is betting that the antibody-drug conjugate format solves it where small molecules alone have not. The company’s HREC approval in Australia clears AN4035, a CEACAM5-targeting ADC carrying a pan-RAS(ON) inhibitor payload, to enter its phase I trial with patient dosing expected in the second half of 2026. Parallel IND filings are in process with the FDA and China’s NMPA, signaling a genuinely global launch strategy rather than a staged regional rollout.
The design logic here is specific and worth unpacking. Approved KRAS G12C inhibitors like sotorasib demonstrated real activity in colorectal, pancreatic, and lung cancers, but their reach is constrained to the G12C mutation subtype and systemic RAS pathway inhibition carries its own toxicity burden. AN4035 uses CEACAM5, an antigen overexpressed across those same tumor types, as the delivery address, concentrating pan-RAS(ON) inhibition at the tumor site while theoretically sparing normal tissue from broad pathway suppression. Preclinical data showed nanomolar to picomolar cytotoxicity in CEACAM5-positive, RAS-addicted cell lines, along with bystander killing and deep regression in CDX and PDX models. Those numbers justify moving forward, though translating picomolar potency in a dish to durable responses in patients is precisely what phase I exists to interrogate.
The trial design adds another layer of ambition. AN4035 will be evaluated not only as monotherapy but in combination with cetuximab, the anti-EGFR antibody already established in colorectal cancer. That combination arm is not incidental. Cetuximab’s activity is notoriously blunted by RAS mutations, which are predictive of non-response. Pairing it with a RAS-suppressing ADC is a rational attempt to rescue a treatment strategy that RAS mutations currently defeat. Whether the pharmacokinetics and tolerability support that combination at therapeutic doses is the central clinical question the trial must answer before any efficacy story can be told.
Australia’s CTN pathway allowed Adlai Nortye to move from HREC approval to trial initiation without waiting for full TGA review, compressing early regulatory friction in a meaningful way. The marker to track here is the dose-escalation safety profile once dosing begins, specifically whether the ADC format genuinely limits systemic RAS pathway toxicity relative to what has been observed with oral pan-RAS inhibitors. That signal, or its absence, will determine whether the RASiCA platform earns broader development investment or remains a preclinical proof of concept that did not survive first human contact.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
